On May 16, 2023 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today described recently presented real-world data that confirm a consistent risk of myelosuppressive events (neutropenia, anemia, thrombocytopenia) across patients with small cell lung cancer (SCLC) being treated with chemotherapy (Press release, G1 Therapeutics, MAY 16, 2023, View Source [SID1234631773]). These findings were presented in a poster session at the 2023 meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), held May 7-10, 2023.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Chemotherapy remains an effective cornerstone treatment for patients with small cell lung cancer; unfortunately, chemotherapy-induced myelosuppression is a known common and debilitating complication associated with these cytotoxic regimens," said Norman Nagl, Ph.D., Vice President of Medical Affairs at G1 Therapeutics. "Despite this, little data have been generated in this tumor type to help clarify and quantify the risk of myelosuppressive events across the spectrum of patients who are treated with chemotherapy for SCLC. For the first time, the results of these analyses show that all patients – of any age, gender, race, stage, ECOG or smoking status, or at any line of chemotherapy – are at similarly high risk for such myelosuppressive events. This continues to underscore the need to ensure that patients receive the most appropriate therapies to reduce that risk and to help improve their chemotherapeutic experience."
Results showed that, among adult patients in this data set diagnosed with SCLC who received chemotherapy, grade ≥3 myelosuppression occurred in 60.9% of patients in the overall population. Further, more than half of the patients experienced grade ≥3 myelosuppression in all subgroups among the overall population, except one subgroup of patients for whom their SCLC stage was not documented at diagnosis (n=15). Multivariate regression analyses identified no significant associations between patient characteristics and myelosuppression; similar findings were observed in age-specific and lineage-specific regression models.
The poster, titled, "An Analysis of Patient Characteristics Associated With Myelosuppression Among Small Cell Lung Cancer Patients Treated in US Community Cancer Care Practices" is available in the scientific publications section of G1’s website.
Study Design
This retrospective observational study used the electronic medical records (EMR) data from the Providence St. Joseph Health (PSJH) and the Providence Cancer Reporting Registry, which included data from 40 oncology clinics associated with community hospitals across seven U.S. states. Adult patients diagnosed with SCLC who received chemotherapy between 2016 and 2018 and had longitudinal laboratory data were included in this study. Patients were followed from the date of the first chemotherapy dose for 12 months, or until the date of the last visit, date of death, or the end of the study period (December 2019), whichever occurred earliest. Percentages of patients with grade ≥3 myelosuppression and grade ≥3 lineage-specific cytopenia were analyzed by patient characteristics. Multivariate logistic regressions were conducted to examine the association between patient characteristics (independent variable) and risk of experiencing at least one grade ≥3 myelosuppression (dependent variable) among the overall population and by age group. In addition, multivariate logistic regressions were conducted to examine association between patient characteristics and risk of myelosuppression in each lineage (anemia, neutropenia, thrombocytopenia).
About Small Cell Lung Cancer
In the United States, approximately 30,000 small cell lung cancer patients are treated annually. SCLC, one of the two main types of lung cancer, accounts for approximately 14% of all lung cancers. SCLC is an aggressive disease and tends to grow and spread faster than NSCLC. It is usually asymptomatic; once symptoms do appear, it often indicates that the cancer has spread to other parts of the body. About 70% of people with SCLC will have cancer that has metastasized at the time they are diagnosed. The severity of symptoms usually increases with increased cancer growth and spread. From the time of diagnosis, the general 5-year survival rate for people with SCLC is 6%. The five-year survival rates for limited-stage (the cancer is confined to one side of the chest) SCLC is 12% to 15%, and for extensive stage (cancer has spread to the other lung and beyond), survival rates are less than 2%. Chemotherapy is the most common treatment for ES-SCLC.